{"entity":{"id":"paper-angiotax-paclitaxel-angiosarcoma-penel-jco-2008","kind":"paper","name":"ANGIOTAX: phase 2 trial of weekly paclitaxel for unresectable angiosarcoma","aka":[],"tldr":"Weekly paclitaxel controlled angiosarcoma in three quarters of patients at two months and produced responses in about one in five, establishing it as a standard first-line chemotherapy for this vascular sarcoma, especially of the scalp and face.","summary":"Phase 2 study of 30 patients with unresectable angiosarcoma treated with weekly paclitaxel 80 mg per square metre.\n\nNon-progression at two months was 74 percent, objective response 19 percent, median progression-free survival 4 months and median overall survival 8 months; responses were more frequent in scalp and face angiosarcomas.","asOf":"2026-09-17","links":[{"label":"J Clin Oncol 2008","url":"https://doi.org/10.1200/JCO.2008.17.3146"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/18809609/"}],"tags":[],"related":[],"cancers":["angiosarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["angiotax"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jco"],"dependsOn":[],"notes":[],"journal":"Journal of Clinical Oncology","year":2008,"doi":"10.1200/JCO.2008.17.3146","pmid":"18809609","authors":"Penel N, Bui BN, Bay JO, et al.","paperType":"observational","findings":["Non-progression rate at two months 74 percent; objective response 19 percent.","Median overall survival 8 months."],"whatItMeans":"Weekly paclitaxel is a standard first-line option for angiosarcoma alongside doxorubicin, and it is also used with radiotherapy for unresectable scalp disease.","caveats":["Small single-arm study; survival remains poor.","The randomised ANNOUNCE and other trials have since compared taxanes with anthracyclines."],"changedPractice":true,"participants":30},"route":"/key-papers/paper-angiotax-paclitaxel-angiosarcoma-penel-jco-2008/","neighbours":{"cancer":[{"id":"angiosarcoma","kind":"cancer","name":"Angiosarcoma","route":"/cancers/angiosarcoma/"}],"trial":[{"id":"angiotax","kind":"trial","name":"ANGIOTAX","route":"/trials/angiotax/"}],"journal":[{"id":"jco","kind":"journal","name":"Journal of Clinical Oncology","route":"/journals/jco/"}]}}